TLT in the oncology arena + a question for BencroThe recent $100M partnership in the oncology arena between MD Anderson, XON and ZIOP is interesting to say the least. Mr Bencro, what is you opinion of their merger, and how do you percieve their chances of controlling the auto immune response? What are their chances of addressing solid tumors and the ballance or should I say battle with toxicology? Their tech has not been proven either..but it is a hot topic...and as they ramp up their dosage to deal with solid tumors they battle larger toxicoligy issues than the Theralase PDCs...maybe? I concede that the implied autoimmune respose from the PDCs is a long shot, but the 100% tumor destruction is a assured. Could it be that TLTs destiny to join this esteemed group and whomp big pharmas butt.
On the other hand.....IF... the human body responds well to our PDC treatment with an autoimmune response , out treatment of cancer will be labeled as a CURE...and will render these heavy hitters efforts obsolete before they are proven. Time might? be on TLTs side, as TLT is more apt to be excused from phase 2 trials, and they are more likely to be pushed into phase 3 trials, given their apoach involves a complex synergy netween drugs, That's my dream, but I concede that the more likely outcome will be a combination of treatments, with the patients being the big winners. Of course I am raising more questions than answers....thats the purpose of a bull board. I am not educated in this field...I am raising speculative questions as a curious investor..
peace and love Aubrey